


|                  |                           |   |
|------------------|---------------------------|---|
| Name             | Takanori Teshima          |  |
| Current Position | Professor                 |   |
| Country          | Japan                     |   |
| Major Field      | GVHD/GVL, CAR-T, COVID-19 |   |

### Educational Background

1986 MD, Kyushu Univ, Fukuoka  
 1997 PhD, Kyushu Univ, Fukuoka  
 1997 Postdoc fellow, Dana-Farber Cancer Institute, Boston  
 1999 Postdoc fellow, Univ of Michigan, Ann Arbor

### Professional Experience

1996 Assistant Professor, Medicine II. Okayama Univ, Okayama  
 2000 Research Investigator, Internal Medicine, Univ of Michigan, Ann Arbor  
 2002 Assistant Professor, Medicine II. Okayama Univ, Okayama  
 2004 Associate Professor, Center for Cellular & Molecular Medicine, Kyushu Univ  
 2012 Professor, Hematology, Hokkaido Univ, Sapporo

### Other Experience and Professional Memberships

2014 Executive Director, Japanese Society of Hematology  
 2015 Executive Director, Japanese Society of Transfusion Medicine & Cell Therapy  
 2020 President, Japanese Society for Transplantation and Cellular Therapy

### Main Scientific Publications

Teshima T, et al: Acute graft-versus-host disease does not require alloantigen expression on host epithelium. *Nature Med* 2002; 8: 575-581.

Asakura S, et al, Teshima T. Alloantigen expression on non-hematopoietic cells reduces GVL effects. *J Clin Invest* 2010; 120: 2370.

Kikushige Y, Teshima T et al. TIM-3 is a promising target to selectively kill AML stem cells. *Cell Stem Cell* 2010; 7: 708

Takashima S, et al, Teshima T. The Wnt agonist R-spondin1 regulates systemic GVHD by protecting intestinal stem cells. *J Exp Med* 2011; 208: 285

Hashimoto D, et al. Pretransplant CSF-1 therapy expands recipient macrophages and ameliorates GVHD after allogeneic HSCT. *J Exp Med* 2011; 208: 1069.

Eriguchi Y, et al, Teshima T. GVHD disrupts intestinal microbial ecology by inhibiting Paneth cell production of  $\alpha$ -defensins. *Blood* 2012; 120: 223.

Kuriyama T, Teshima T et al. Engulfment of hematopoietic stem cells caused by down-

regulation of CD47 is critical in the pathogenesis of hemophagocytic lymphohistiocytosis. *Blood* 2012; 120: 4058.

Shima T, Teshima T et al. Quantification of hematogones at the time of engraftment is a useful prognostic indicator in allogeneic stem cell transplantation. *Blood* 2013; 121: 840.

Aoyama K, Teshima T et al. Inhibiting retinoic acid signaling ameliorates graft-versus-host disease by modifying T-cell differentiation and intestinal migration. *Blood* 2013; 122: 2125.

Shimoji S, et al, Teshima T. Graft-versus-host disease targets ovary and causes female infertility in mice. *Blood* 2017; 129: 1216.

Hayase E, et al, Teshima T. R-Spondin1 expands Paneth cells and prevents dysbiosis induced by graft-versus-host disease. *J Exp Med* 2017; 214: 3507.

Yamakawa T, et al, Teshima T. Vitamin A-coupled liposomes containing siRNA against HSP47 ameliorate skin fibrosis in chronic graft-versus-host disease. *Blood* 2018; 131: 1476.

Takahashi S, et al, Teshima T. Ruxolitinib protects skin stem cells and maintains skin homeostasis in murine graft-versus-host disease. *Blood* 2018.

Mathew NR, Teshima T, et al. Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells. *Nat Med* 2018; 24: 282.

Toffalori C, Teshima T, et al. Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation. *Nat Med* 2019; 25: 603.

Stein-Thoeringer CK, Teshima T, et al. Lactose drives Enterococcus expansion to promote graft-versus-host disease. *Science* 2019; 366: 1143.

Peled JU, Teshima T, et al. Microbiota as Predictor of Mortality in Allogeneic Hematopoietic-Cell Transplantation. *N Engl J Med* 2020; 382: 822

Ara T, et al, Teshima T: Intestinal goblet cells protect against GVHD after allogeneic stem cell transplantation via Lypd8. *Sci Transl Med*. 2020;12(550):eaaw0720

Yokota I, et al Teshima T. Mass screening of asymptomatic persons for SARS-CoV-2 using saliva. *Clin Infect Dis* 2020: ciaa1388

Yokota I, et al, Teshima T: A novel strategy for SARS-CoV-2 mass screening with quantitative antigen testing of saliva: a diagnostic accuracy study. *Lancet Microbe*. 2021 Aug;2(8): e397-e404

Zeiser R, et al, Teshima T, Locatelli F: Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease. *N Engl J Med*. 2021;385:228-238